Jides (levonorgestrel) 13.5 mg.


Manufacturer: Germany

insufficient exocrine function of the pancreas in chronic pancreatitis; digestive disorders such as dyspepsia, belching, pain in the epigastric region, a feeling of discomfort and overcrowding in the stomach, flatulence, nausea improvement of digestive processes in case of violation of the regime of rational nutrition (consumption of alcohol, a large amount of food, fatty or unusual food, etc.); preparation for x-ray and ultrasound examinations of abdominal organs; intolerance to milk and dairy products; improvement of digestive processes in ulcerative colitis, irritable bowel syndrome, chronic enteritis and enterocolitis, as well as after gastric resection.


Jides Storage
active substance: levonorgestrel;

1 intrauterine system contains levonorgestrel 13.5 mg;

Jides excipients: polydimethylsiloxane elastomer core;

silicon-filled polydimethylsiloxane elastomer; polyethylene; barium sulfate; iron oxide (E 172); silver (E 174).

Jides Dosage form
Intrauterine system with levonorgestrel.

Main physical and chemical properties: intrauterine system with a silver ring, without visible damage. The color of the tank with the active substance is whitish or pale yellow.

Pharmacotherapeutic group
Contraceptive for topical use. Intrauterine contraceptive. Plastic IUD with progestin.

ATX code G02B A03.

Pharmacological properties


The Jades® system has a predominantly local progestogenic effect on the uterine cavity.

High concentrations of levonorgestrel in the endometrium inhibit the synthesis of endometrial estrogen and progesterone receptors. The endometrium becomes relatively insensitive to circulating estradiol, there is a significant antiproliferative effect. Morphological changes of the endometrium and a weak reaction to a foreign body were observed when using the Jades® system. Thickening of cervical mucus prevents the passage of sperm through the cervical canal. The local microenvironment of the uterus and fallopian tubes inhibits sperm motility and function, preventing fertilization. In clinical studies of the Jades® system, ovulation was observed in the majority of women in the relevant subgroup. Signs of ovulation during the first year were observed in 34 out of 35 women, during the second year in 26 out of 27 women, during the third year – in all 26 women.

Clinical efficacy and safety.

The contraceptive efficacy of the Jades® system was evaluated in a clinical study involving 1,432 women aged 18-35 years, including 38.8% (556) of women who never gave birth, of whom 83.6% (465) had no pregnancy. . For 1 year the Pearl index was 0.41 (95% confidence interval 0.13-0.96), and after 3 years the Pearl index was 0.33 (95% confidence interval 0.16-0.60). The frequency of contraceptive failures for 1 year was about 0.4%, the overall failure rate was about 0.9% for 3 years. Pregnancy due to unnoticed expulsion and perforation is also taken into account in this failure rate. The use of the system with levonorgestrel does not affect a woman’s future fertility. Based on data from the use of IUDs with a higher dose of levonorgestrel, approximately 80% of women who wished to become pregnant conceived within the first 12 months after removal of the system.

Contraception for three years.

Acute or recurrent pelvic inflammatory disease or diseases associated with an increased risk of pelvic infection.
Acute cervicitis or vaginitis.
Postpartum endometritis or infected abortion in the last three months.
Cervical intraepithelial neoplasia to complete convalescence.
Malignant tumors of the cervix or uterus.
Progestogen-dependent tumors, including breast cancer.
Unexplained abnormal uterine bleeding.
Congenital or acquired pathologies of the uterus, including leiomyomas, which may interfere with the introduction and / or maintenance of the intrauterine system (for example, if they deform the uterine cavity).
Acute liver disease or liver tumors.
Hypersensitivity to the active substance or to any of the excipients.